期数： 2025年6月刊 分类： 会员服务—中国智能手机盖板月度市场发展趋势概况 * 请 会 员 单 位 通 过 会 员 登 陆 平 台 下 载 或 邮 件 接 收 此 份 报 告 。 * 如 需 了 解 更 多 相 关 信 息 ， 请 订 阅 C I N N O Re s e a r c h 《 月 度 中 国 智 能 手 机 盖 板 市 场 分 析 报 告 》 。 联系我们 马女士 Ms . Ceres TEL：（+86）137-7604-9049 Emai l：CeresMa@cinno.com.cn 1. 01'24~05'25 中国市场智能手机前盖搭载量渗透率变化趋势 2. 01'24~05'25 中国市场折叠屏智能手机UTG、CPI前盖使用量变化情况 3. 01'24~05'25 中国市场折叠屏智能手机前盖搭载量渗透率变化情况 4. 01'24~05'25 中国市场折叠屏智能手机UTG前盖搭载量品牌占比情况 5. 01'24~05'25 中国市场折叠屏智能手机CPI前盖搭载量品牌占比情况 6. 01'24~05'25 中国市场苹果智能手机前盖规格别销量及占比情况 7. 01'24~05'25 中国 ...

Efficacy Results - Atacicept demonstrated long-term stabilization of eGFR (estimated glomerular filtration rate) in IgAN patients over 96 weeks[31] - Atacicept treatment resulted in a sustained 66% reduction in Gd-IgA1 levels[20] - There was a notable 52% reduction in proteinuria (UPCR) with atacicept treatment over the 96-week study period[20] - Atacicept led to a 75% resolution of hematuria in treated participants[20] - The annualized eGFR slope with atacicept was -0.6 mL/min/1.73 m2 per year, comparable to the general population without kidney disease[20] Safety Profile - Atacicept was generally well-tolerated over 96 weeks, with an adverse event profile consistent with the initial 36-week randomized period[27] - During the double-blind phase, 73% of participants in the atacicept group experienced treatment-emergent adverse events (TEAEs)[27] - In the open-label extension (OLE) phase, 77% of participants experienced TEAEs[27] - Serious TEAEs were reported in 2% of participants during the double-blind phase and 11% during the OLE phase[27] - Discontinuation due to TEAEs occurred in 1% of participants during the double-blind phase and 2% during the OLE phase[27]

随着人们对食材储存多样化需求激增，冰箱冷冻空间不足成为许多家庭的困扰。同时，传统冷柜结霜问题不仅影 响存储空间，还会降低制冷效果、增加耗电量。澳柯玛风冷无霜冷柜BC/BD-306WDHXF针对这些痛点，凭借多项 创新技术和优异性能，成为家庭储鲜的理想之选。 你是否还在为冰箱冷冻层塞不下海鲜、饺子、冷食而烦恼？是否还在忍受传统冷柜厚厚的冰霜和费时费力的除霜 工作？近日，澳柯玛推出全新风冷无霜冷柜BC/BD-306WDHXF，旨在解决家庭冰箱冷冻空间不足以及传统冷柜结 霜难题，为消费者带来更优质的储鲜解决方案。 该冷柜采用真风冷技术，实现零结霜效果。通过复合回风系统、多维风幕锁冷技术等，在箱体内部形成多维立体 风冷循环，冷气快速均匀环绕，无需手动除霜，让用户告别繁琐的清洁工作，也避免霜层对冷柜空间的占用。 深冷速冻功能是其一大亮点。冷柜可实现-40℃深冷速冻，能让食材急速穿越冰晶大量生成的"危险地带"，将冰晶 颗粒控制在微米级，锁住食材的营养与鲜味。无论是新鲜的肉类、海鲜，还是珍贵的滋补食材，都能在适宜的温 度环境中得以保存。 在控温技术上，该冷柜配备电脑控温系统，可实现0.1℃精准调温。同时，一机四用功能满足了 ...

在A股6月震荡上行、上证指数突破3400点创年内新高的市场背景下，第八届新财富最佳投资顾问评 选"投资管理能力评价"（2025年5月1日至10月31日）进程已过1/3。优秀投顾展现强劲实力，业绩全 面跑赢大盘，其超额收益优势持续扩大，成为震荡市中的一抹亮色。 作为中国证券行业最大且最具影响力的投顾竞技平台，本届评选共吸引来自90家证券公司的39893名 投顾参评，创历届参评人数新高。那么，排名前列的投顾究竟来自于哪些券商？他们的投资秘籍又是 什么？且看下文。 0 1 业绩高歌猛进 超额收益显著 本月参评投顾业绩也高歌猛进。股票交易组TOP10平均收益率高达47.41%，TOP300强势斩获27.19% 回报，展现出顶尖梯队的强大爆发力与整体阵容的稳健实力。本月前三甲仅 东方证券上海浦东新区张 杨路证券营业部王宇航 蝉联，位居全国第二名。第一名和第三名分别是 广发证券浙江分公司刘环宇 和国联民生证券浙江分公司雷梦瑶 。 0 2 ETF组TOP200平均收益率高达17.34% 第八届新财富最佳投资顾问评选 NewFortune Best Investment Advisor 协办单位 > 朝阳永续 | Go-Go ...

Group Overview - The Ministry of Finance of the Republic of Lithuania announced the selection of six independent members for the Group's Supervisory Board, with applications open until 24 July 2025 [1][2] - The current term of the Supervisory Board ends on 25 October 2025, and the selection process is expected to be completed before this date [4] Selection Process - An international selection commission will oversee the candidate selection, comprising representatives from various governmental bodies and an executive search agency [2][3] - Candidates will be evaluated based on general, special, and independence requirements as outlined in the advertisement [3] Supervisory Board Structure - The Supervisory Board will consist of nine members: six independent members and three civil servants appointed by the Ministry of Finance [5] - The Board will establish three advisory committees: the Audit and Risk Committee, the Nomination and Remuneration Committee, and the Sustainability Committee [5] Future Appointments - The selection of civil servants for the Supervisory Board will occur at a later stage, following specific guidelines [6] - The Group will provide updates regarding the selection process in accordance with legal requirements [7]

半年总结：当我们面前不再只有牛市一条路 https://www.jisilu.cn/question/510960 还个愿，曾经10年10倍梦想 https://www.jisilu.cn/question/510886 集思录(www.jisilu.cn)是一个以数据为本的投资理财社区，专注于新股、可转债、债券、封闭 基金等数据服务。我们的理念是在保证本金安全的前提下，使资产获得稳健增长。 快捷查询： 张家界为何这么能亏？ https://www.jisilu.cn/question/511021 搜索公众号"jisilu8"添加我们 请教一下大家的现金管理方案 https://www.jisilu.cn/question/511057 关注集思录微信 特别提示 本文不构成任何投资建议，仅为信息分享。任何因本文导致的投资行为发生的亏损，本公众号 及作者概不承担任何责任。 ...

儿子生日的时候，弟媳还有她的20多岁的亲戚来我家做客。期间聊起旅游要趁早去，晚去了 感觉不一样。人生有些必须做的事情要早做。当场我是反对这个观点的，但是没有办法说服 他们。昨天和爱人聊到年轻消费主义观点的时候，又提到了这个事情。 有云：不到长城非好汉；也有60、70者云：拍照要去天安门；亦有70、80者有云：此生必驾 318；更有00者云：不去网红大理、重庆、淄博等城市枉毕业。其实不是每个群体都有吸引 他们的执念，而是每个群体都有针对性的广告宣传。 有人担心，现在年轻时候不走，以后没有体力。我不以为然。50之前，都是年富力强。50岁 去黄山爬不上去是因为没有锻炼保持体力。只需适当锻炼几年，照样可以像20多岁一样，经 历充沛。 有人担心，现在年轻时候不逛，以后没有心境。我不以为然。心境是人的主观感受，年长的 人暂离家人、解开束缚一样可以去静安路的酒吧夜蒲。 有人担心，现在年轻时候不去，以后不适合去年轻人合适的景点。然而，并没有什么景点要 求一定要年轻人去。至少没有明令超过XX不得进入。若干年后，我依然会独自一人坐在解放 碑看美女，火锅后找个地方按脚。 我大学毕业后因为工作原因短暂地去过北京、重庆、深圳、上海、香 ...

Pipeline and Drug Candidates - Revolution Medicines has a deep science-driven pipeline of targeted therapies for RAS-addicted cancers, with drug candidates expected to enter the clinic in 2022 [13, 14] - RMC-6236 is a first-in-class RASMULTI(ON) inhibitor with broad potential against RAS-addicted cancers [22] - RMC-6291 is a mutant-selective RAS(ON) inhibitor with best-in-class potential for KRASG12C cancers [44] - RMC-9805 is a mutant-selective RAS(ON) inhibitor with best-in-class potential for KRASG12D cancers [62] - RMC-8839 is a first-in-class mutant-selective RAS(ON) inhibitor for KRASG13C cancers [74] Clinical Priorities and Activities - Revolution Medicines plans to submit INDs for RMC-6236 and RMC-6291 in the first half of 2022 and initiate single-agent dose escalation studies [42, 60] - The company aims to complete enrollment in RMC-4630-03 and provide preliminary evaluation in the second half of 2022 [98] - Revolution Medicines anticipates submitting INDs for RMC-9805 in the first half of 2023 and RMC-8839 in the second half of 2023 [118] RAS-Addicted Cancers and Patient Numbers - RAS proteins drive 30% of human cancers [7, 122] - There are an estimated 137,000 new KRASG12X patients per year in the U S [23] - There are approximately 29,000 new KRASG12C patients per year in the U S [45] - There are approximately 55,000 new KRASG12D patients per year in the U S [63] - There are approximately 3,000 new KRASG13C patients per year in the U S [75] Financial Position - Revolution Medicines had $577.1 million in cash, cash equivalents, and marketable securities as of December 31, 2021 [120]

Pipeline and Drug Candidates - Revolution Medicines is developing a deep pipeline of targeted therapies for RAS-addicted cancers, with the first two drug candidates expected to enter the clinic in 2022 [13] - RMC-6236 is a first-in-class RASMULTI(ON) inhibitor with potential against various RAS-addicted cancers, targeting approximately 137,000 new KRASG12X patients per year in the U S [19, 20] - RMC-6291 is a mutant-selective RAS(ON) inhibitor with best-in-class potential for KRASG12C cancers, addressing approximately 29,000 new KRASG12C patients per year in the U S [38, 39] - RMC-9805 is a first-in-class mutant-selective RAS(ON) inhibitor for KRASG12D cancers, targeting approximately 55,000 new KRASG12D patients per year in the U S [59, 60] - RMC-8839 is a first-in-class mutant-selective RAS(ON) inhibitor for KRASG13C cancers, addressing approximately 3,000 new KRASG13C patients per year in the U S [69, 70] Preclinical Data and Activity - RMC-6236 demonstrated robust anti-tumor activity in cancer models, with 44% ORR (8/18) in NSCLC, 53% ORR (8/15) in PDAC, and 61% ORR (11/18) in CRC [24] - RMC-6291 showed superior outcomes in a mouse clinical trial with KRASG12C NSCLC models, achieving 72% ORR (18/25) and 92% DCR (23/25) [43] - Preclinical research indicates that RMC-6236 and RMC-6291 exhibit anti-tumor immunity in vivo and strong additivity with checkpoint inhibitors [29, 52] Clinical Development and Strategy - Revolution Medicines plans to initiate single-agent dose escalation for RMC-6236 in patients with cancers harboring KRASG12X mutations, focusing on NSCLC, pancreatic cancer, and CRC [36] - The company also intends to start single-agent dose escalation for RMC-6291 in KRASG12C tumors, including expansion cohorts in select populations like NSCLC [58] - RMC-4630, a RAS companion inhibitor, is undergoing clinical combination studies, including with sotorasib and adagrasib, to address resistance mechanisms in KRASG12C tumors [91, 93] Financial Status - As of March 31, 2022, Revolution Medicines had approximately $518 8 million in cash, cash equivalents, and marketable securities [125] - The company anticipates a GAAP net loss of $260 million to $290 million for 2022, including $35 million to $40 million in non-cash stock-based compensation expense [125, 126]

Overview - Revolution Medicines is targeting RAS-addicted cancers, which are driven by RAS proteins and affect approximately 30% of human cancers[6, 8, 119] - The company is developing RAS(ON) inhibitors and RAS companion inhibitors to address this high unmet need[6, 11] RMC-6236 (RASMULTI Inhibitor) - RMC-6236 is a first-in-class RASMULTI(ON) inhibitor with potential against various RAS-addicted cancers, targeting approximately 137,000 new KRASG12X patients per year in the U S [17, 18] - Preclinical data shows robust anti-tumor activity in cancer models with common RAS variants, including KRASG12D, KRASG12V, KRASG12R, and KRASG12C[20] - In preclinical studies, RMC-6236 demonstrated a 44% Objective Response Rate (ORR) and 56% Disease Control Rate (DCR) in NSCLC models, 61% ORR and 89% DCR in PDAC models, and 53% ORR and 100% DCR in CRC models[24] RMC-6291 (KRASG12C Inhibitor) - RMC-6291 is a mutant-selective RAS(ON) inhibitor with best-in-class potential for KRASG12C cancers, addressing approximately 29,000 new patients per year in the U S [33, 34] - Preclinical studies in KRASG12C NSCLC models showed a 72% ORR and 92% DCR with RMC-6291, compared to 52% ORR and 72% DCR with Adagrasib[39] - RMC-6291 also demonstrated anti-tumor immunity in vivo and strong additivity with checkpoint inhibitors[48] RMC-9805 (KRASG12D Inhibitor) - RMC-9805 is a first-in-class mutant-selective RAS(ON) inhibitor for KRASG12D cancers, targeting approximately 55,000 new patients per year in the U S [51, 52] - Preclinical data shows rapid, deep, and sustained regressions in KRASG12D lung, pancreatic, and colorectal cancers[53] - In preclinical studies, RMC-9805 demonstrated a 64% ORR and 68% DCR across various KRASG12D cancer models[61] RMC-8839 (KRASG13C Inhibitor) - RMC-8839 is a first-in-class mutant-selective RAS(ON) inhibitor for KRASG13C cancers, addressing approximately 3,000 new patients per year in the U S [64, 65] - Preclinical data shows rapid, deep, and sustained regressions in KRASG13C lung cancers[66] Financial Status - As of September 30, 2022, Revolution Medicines had $655 million in cash, cash equivalents, and marketable securities, projecting funding for planned operations through 2024[116] - The company anticipates a 2022 GAAP net loss of $260 million to $280 million, including approximately $30 million to $35 million in non-cash stock-based compensation expense[116]